News Sentiment

CELC sentiment intelligence

Celcuity LLC news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 107.58 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

74/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 3

high-authority source matches

Trend context Trend inactive

-0.3% over one week, +21.5% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

A Quick Look at Today's Ratings for Celcuity(CELC.US), With a Forecast Between $155 to $178

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 74/100 classification
One-week reaction -0.3% Price digesting
Trend fit Trend inactive 21.5% over four weeks
Fair value 175.5% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 17
Neutral 29
Negative 11

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 11
TradingView 11
Investing.com 4
Moomoo 3
Seeking Alpha 2
GuruFocus 2
BioSpace 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 22
Earnings 19
Regulatory and legal 13
Analyst action 2
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Kavout | AI Direct company coverage

Celcuity's REVTORPYK Approval: A Multi-Billion Dollar Breakthrough Despite High Expectations

Celcuity Inc. secured early FDA approval for REVTORPYK (gedatolisib) for HR+/HER2- breast cancer, signaling a potential multi-billion dollar market opportunity. The drug, a first-in-class pan-PI3K/mTOR inhibitor, demonstrated superior efficacy and a favorable safety profile compa

Tone
Positive 73/100
Event
Regulatory and legal
Published
16 Jul 2026 10:13
Source
Kavout | AI
BioPharma Dive Direct company coverage

Celcuity gains FDA approval for closely watched breast cancer drug

Celcuity received FDA approval for its breast cancer drug, Revtorpyk, for use in specific combinations for advanced ER-positive, HER2-negative breast cancer patients without a PIK3CA mutation. Despite the approval, Celcuity's shares fell by nearly 20% due to a delayed launch time

Tone
Neutral 50/100
Event
Regulatory and legal
Published
15 Jul 2026 16:10
Source
BioPharma Dive
BioWorld News Direct company coverage

Celcuity’s Revtorpyk wins FDA nod in breast cancer

Celcuity Inc. received FDA approval for Revtorpyk (gedatolisib) for a subset of breast cancer patients, marking the company's first commercial product and a new treatment option. Despite this positive news, investor excitement was dampened by an unanticipated launch delay, causin

Tone
Negative 32/100
Event
Regulatory and legal
Published
15 Jul 2026 16:10
Source
BioWorld News
BioSpace Direct company coverage

Celcuity wins breast cancer nod, securing ‘differentiated foothold’ in market

Celcuity has received FDA approval for its kinase inhibitor gedatolisib, branded as Revtorpyk, for specific patients with advanced HR-positive, HER2-negative breast cancer without PIK3CA mutations. This approval provides Celcuity with a unique position in the market, distinguishi

Tone
Positive 73/100
Event
Regulatory and legal
Published
15 Jul 2026 11:41
Source
BioSpace
Market source Direct company coverage

Celcuity gains FDA approval for closely-watched breast cancer drug

Celcuity received FDA approval for its breast cancer drug Revtorpyk, to be used in combination with hormone therapy and Pfizer’s Ibrance for certain advanced ER-positive, HER2-negative patients. Despite this regulatory win, Celcuity's shares fell due to unexpected launch timing a

Tone
Positive 60/100
Event
Regulatory and legal
Published
15 Jul 2026 07:18
Source
Market source
BioSpace Direct company coverage

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer

Celcuity Inc. announced that the FDA has approved REVTORPYK™ (gedatolisib) for the treatment of HR+/HER2-, PIK3CA wild-type locally advanced or metastatic breast cancer. This approval is based on positive results from the Phase 3 VIKTORIA-1 trial, which showed significant improve

Tone
Positive 90/100
Event
Earnings
Published
15 Jul 2026 04:10
Source
BioSpace
Fierce Pharma Direct company coverage

With FDA approval for its breast cancer blockbuster hopeful, Celcuity could ‘belong in the hands’ of a Big Pharma

Celcuity has received FDA approval for its new small molecule inhibitor, Revtorpyk (gedatolisib), for previously treated hormone receptor-positive, HER2-negative breast cancer patients without PIK3CA mutations. This drug has blockbuster potential and could become a new standard o

Tone
Neutral 50/100
Event
Regulatory and legal
Published
14 Jul 2026 21:56
Source
Fierce Pharma
Market source Direct company coverage

CELC Stock Clocks Best Day In About 2 Months On First FDA Approval For Cancer Drug

Celcuity Inc. (CELC) shares surged 7% after the FDA approved its cancer drug, gedatolisib, in combination with fulvestrant, with or without Pfizer's palbociclib, for advanced hormone receptor-positive, HER2-negative breast cancer. This marks Celcuity's first marketed product, tra

Tone
Positive 93/100
Event
Regulatory and legal
Published
14 Jul 2026 21:24
Source
Market source
GlobeNewswire Direct company coverage

Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib)

Celcuity Inc. announced that the FDA approved REVTORPYK™ (gedatolisib) for the treatment of HR+/HER2- locally advanced or metastatic breast cancer without a PIK3CA mutation. This approval is based on positive Phase 3 VIKTORIA-1 trial results, showing significant reduction in dise

Tone
Positive 95/100
Event
Earnings
Published
14 Jul 2026 21:03
Source
GlobeNewswire
SRN News Direct company coverage

US FDA approves Celcuity’s breast cancer drug

The U.S. FDA has approved Celcuity’s drug, Revtorpyk (gedatolisib), for an advanced form of breast cancer, marking the company's first product to gain market entry. This approval is based on late-stage data showing the drug significantly reduced the risk of disease progression or

Tone
Positive 71/100
Event
Regulatory and legal
Published
14 Jul 2026 21:03
Source
SRN News
TradingView Direct company coverage

CELC6416934 Bond Coupon Profile — Rate & Payments

This article provides the coupon profile for the CELC6416934 bond issued by Celcuity, Inc. It details the current coupon rate of 0.25% and notes that the next interest payment is scheduled for February 1, 2027. The article encourages users to unlock full data for more in-depth bo

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 07:42
Source
TradingView
Simply Wall Street Direct company coverage

Will Celcuity's (CELC) Broad Russell Index Removal Reshape Its Gedatolisib-Centric Investment Narrative

Celcuity Inc. (CELC) was removed from several Russell indices, which may impact its visibility and liquidity. This removal does not, however, alter the core investment narrative centered on the prospects of its drug gedatolisib and upcoming regulatory milestones. The article high

Tone
Negative 39/100
Event
Regulatory and legal
Published
10 Jul 2026 01:39
Source
Simply Wall Street
Moomoo Direct company coverage

Celcuity Rises as Investors Focus on Near-Term FDA Catalyst for Gedatolisib

Celcuity's stock rose as investors anticipate a near-term FDA catalyst for its drug candidate, gedatolisib. The company submitted a BTD application for gedatolisib in 2L/3L HR+/HER2- metastatic breast cancer, with a response expected by August 12. Positive outcomes from this regu

Tone
Positive 75/100
Event
Market update
Published
08 Jul 2026 13:10
Source
Moomoo
StocksToTrade Direct company coverage

CELC Stock Holds Trend As Opaque Insider Filings Hit Tape

Celcuity Inc. (CELC) surged over 6.5% due to positive breast cancer trial results, despite opaque insider filings. Two Form 4 filings indicated changes in beneficial ownership but lacked crucial details like transaction size or direction, making it difficult for traders to assess

Tone
Positive 67/100
Event
Earnings
Published
07 Jul 2026 20:11
Source
StocksToTrade
Simply Wall Street Direct company coverage

Is Celcuity (CELC) Undervalued After Its Removal From Major Russell Indices?

Celcuity (CELC) was recently removed from major Russell indices, which could impact its trading flows. Despite this, the stock has shown strong recent price momentum. The company is currently pre-revenue but analysts forecast significant future revenue and profitability, leading

Tone
Positive 66/100
Event
Earnings
Published
07 Jul 2026 01:11
Source
Simply Wall Street
Stock Traders Daily Direct company coverage

Precision Trading with Celcuity Inc. (CELC) Risk Zones

This article provides a precision trading analysis for Celcuity Inc. (CELC) using AI models, highlighting strong sentiment across all horizons and an exceptional risk-reward setup. It outlines three distinct trading strategies—Position Trading, Momentum Breakout, and Risk Hedging

Tone
Positive 74/100
Event
Market update
Published
06 Jul 2026 10:39
Source
Stock Traders Daily